primary effusion lymphoma
primary effusion lymphoma
Explore linked clinical trials. Standard reference: MONDO:001884210 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer | AIDS, B-cell neoplasm, Blood-Borne Infections, DNA Virus Infections, Genital Diseases, HIV infectious disease, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Kaposi's sarcoma, Multi-centric Castleman's Disease, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, RNA Virus Infections, Slow Virus Diseases, Urogenital Diseases, immune system disorder, immunoproliferative disorder, inborn error of immunity, infectious disease, lentivirus infection, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, primary effusion lymphoma, sarcoma, sexually transmitted disease, uterine carcinosarcoma, vascular cancer, viral infectious disease, viral sexually transmitted disease | Recruiting | Not stated | 2026-10-08 | NCT00006518 | |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | B-cell neoplasm, B-cell non-Hodgkin lymphoma, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma, primary central nervous system lymphoma, primary effusion lymphoma | Recruiting | Phase 1 / Phase 2 | 2026-10-01 | NCT06343311 | |
| Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease | B-cell neoplasm, DNA Virus Infections, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Kaposi's sarcoma, Multi-centric Castleman's Disease, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, primary effusion lymphoma, sarcoma, vascular cancer, viral infectious disease | Recruiting | Phase 2 | 2026-09-25 | NCT05907759 | |
| Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, AIDS-Related, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, primary effusion lymphoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-26 | NCT02911142 | |
| Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis | AIDS, B-cell neoplasm, Blood-Borne Infections, Bone Diseases, Metabolic, DNA Virus Infections, Genital Diseases, HIV infectious disease, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Kaposi's sarcoma, Multi-centric Castleman's Disease, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Nutritional and Metabolic Diseases, RNA Virus Infections, Slow Virus Diseases, Urogenital Diseases, bone disorder, immune system disorder, immunoproliferative disorder, inborn error of immunity, infectious disease, lentivirus infection, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, metabolic disease, musculoskeletal system disorder, neoplasm, primary effusion lymphoma, sarcoma, sexually transmitted disease, uterine carcinosarcoma, vascular cancer, viral infectious disease, viral sexually transmitted disease | Active, not recruiting | Not stated | 2026-08-25 | NCT04742387 | |
| Natural History of KSHV-Associated Multicentric Castleman s Disease | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, primary effusion lymphoma | Recruiting | Not stated | 2026-08-24 | NCT04968288 | |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, plasmablastic lymphoma, primary effusion lymphoma | Not yet recruiting | Phase 1 | 2026-08-13 | NCT07649304 | |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | ALK-positive large B-cell lymphoma, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, diffuse large B-cell lymphoma, diffuse large B-cell lymphoma activated B-cell type, diffuse large B-cell lymphoma germinal center B-cell type, diffuse large B-cell lymphoma of the central nervous system, immune system disorder, immunoproliferative disorder, intravascular large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphomatoid granulomatosis, lymphoproliferative syndrome, neoplasm, plasmablastic lymphoma, precancerous condition, primary effusion lymphoma, viral infectious disease | Active, not recruiting | Phase 2 | 2026-05-12 | NCT03038672 | |
| Exploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA Vaccine | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, primary effusion lymphoma | Not yet recruiting | Early phase 1 | 2026-05-01 | NCT07563023 | |
| Study of SGR-1505 in Mature B-Cell Neoplasms | ALK-positive large B-cell lymphoma, B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Burkitt lymphoma, Chronic Disease, DNA Virus Infections, Digestive System Diseases, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, T-cell/histiocyte rich large B cell lymphoma, Tumor Virus Infections, Waldenstrom macroglobulinemia, cardiovascular disorder, diffuse large B-cell lymphoma, digestive system disorder, follicular lymphoma, hematologic disorder, hemorrhagic disease, high grade B-cell lymphoma, hypertrophic pyloric stenosis, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoplasmacytic lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, monoclonal gammopathy, neoplasm, neoplasm of mature B-cells, nodal marginal zone B-cell lymphoma, non-Hodgkin lymphoma, plasma cell neoplasm, plasmablastic lymphoma, primary cutaneous follicle center lymphoma, primary effusion lymphoma, pyloric stenosis, splenic marginal zone lymphoma, stomach disorder, vascular disorder, vascular hemostatic disease, viral infectious disease | Recruiting | Phase 1 | 2026-02-13 | NCT05544019 |